A Study of Bi-Ligand-Drug Conjugate CBP-1019 in Patients With Advanced Solid Tumors
Coherent Biopharma (Hefei) Co., Ltd.
Coherent Biopharma (Hefei) Co., Ltd.
Beijing Friendship Hospital
European Institute of Oncology
SpotitEarly
Central South University
University Hospital, Ghent
Lebanese University
Massachusetts General Hospital
Kineta Inc.
Shanghai Yunying Medical Technology
Research and Practical Clinical Center for Diagnostics and Telemedicine Technologies of the Moscow Health Care Department
Shanghai Yunying Medical Technology
Université Sorbonne Paris Nord
Chongqing Precision Biotech Co., Ltd
Assistance Publique - Hôpitaux de Paris
University of Kansas Medical Center
Provectus Pharmaceuticals
Blue Note Therapeutics
Imperial College London
Weprom
TScan Therapeutics, Inc.
Shanghai Fengxian District Central Hospital
Jerome Canady Research Institute for Advanced Biological & Technological Sciences
SpeciCare
MetiMedi Pharmaceuticals
Institut Paoli-Calmettes
Sun Yat-sen University
Petra Pharma
The First Affiliated Hospital of Dalian Medical University
The First Affiliated Hospital of Dalian Medical University
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
National Taiwan University Hospital
Peking Union Medical College
M.D. Anderson Cancer Center
KU Leuven
Xuanwu Hospital, Beijing
Biological Dynamics
Centre Hospitalier Universitaire de Besancon
Southwest Hospital, China
SPGO Research Mannheim GmbH
Shenzhen Second People's Hospital
The Cooper Health System
ChineseAMS
Tianjin Medical University Cancer Institute and Hospital
Sheba Medical Center
BioSense Medical LTD
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Meir Medical Center
National Cancer Center, Korea